May 4, 2020 -- Adare Pharmaceuticals on April 30 acquired pharmaceutical technology firm Orbis Biosciences. Financial details were not disclosed. The acquisition will enhance Adare's ability to manufacture products for the global pharmaceutical, animal health, and over-the-counter markets.
The deal will boost Adare's contract development and manufacturing organization business, it said. Orbis uses a single-step manufacturing process called Precision Particle Fabrication to produce drug particles that can be dosed orally or otically or injected, Adare Pharmaceuticals said. The manufacturing process consists of three platforms: Optimµm for oral delivery, Unisun for otic delivery, and Stratµm for injectable delivery, according to Adare.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
